143 related articles for article (PubMed ID: 18671331)
1. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.
Lutt JR; Pisculli ML; Weinblatt ME; Deodhar A; Winthrop KL
J Rheumatol; 2008 Aug; 35(8):1683-5. PubMed ID: 18671331
[No Abstract] [Full Text] [Related]
2. Mycobacterium kansasii Infection in a Patient Receiving Biologic Therapy-Not All Reactive Interferon Gamma Release Assays Are Tuberculosis.
Saleem N; Saba R; Maddika S; Weinstein M
Am J Med Sci; 2017 Apr; 353(4):394-397. PubMed ID: 28317629
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody.
Czaja CA; Merkel PA; Chan ED; Lenz LL; Wolf ML; Alam R; Frankel SK; Fischer A; Gogate S; Perez-Velez CM; Knight V
Clin Infect Dis; 2014 Mar; 58(6):e115-8. PubMed ID: 24336756
[TBL] [Abstract][Full Text] [Related]
4. Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease.
Malkin J; Shrimpton A; Wiselka M; Barer MR; Duddridge M; Perera N
J Med Microbiol; 2009 Mar; 58(Pt 3):371-373. PubMed ID: 19208889
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.
Browne SK; Zaman R; Sampaio EP; Jutivorakool K; Rosen LB; Ding L; Pancholi MJ; Yang LM; Priel DL; Uzel G; Freeman AF; Hayes CE; Baxter R; Cohen SH; Holland SM
Blood; 2012 Apr; 119(17):3933-9. PubMed ID: 22403254
[TBL] [Abstract][Full Text] [Related]
6. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients.
Majmudar S; Hall HA; Zimmermann B
J Clin Rheumatol; 2009 Oct; 15(7):338-40. PubMed ID: 20009968
[TBL] [Abstract][Full Text] [Related]
7. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
8. Therapy: rituximab and PML risk-informed decisions needed!
Calabrese LH; Molloy ES
Nat Rev Rheumatol; 2009 Oct; 5(10):528-9. PubMed ID: 19798025
[No Abstract] [Full Text] [Related]
9. Trigger finger due to tenosynovitis from Mycobacterium kansasii infection in an immunocompetent patient.
Mejia H; Ryzewicz M; Scott F
Orthopedics; 2007 Dec; 30(12):1055-6. PubMed ID: 18198779
[No Abstract] [Full Text] [Related]
10. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Hradilek P; Zeman D; Tudik I; Zapletalova O; Ulmann V
Mult Scler; 2014 Apr; 20(5):639-40. PubMed ID: 23959714
[No Abstract] [Full Text] [Related]
11. Bacteremia caused by Mycobacterium wolinskyi.
Chen YC; Jou R; Huang WL; Huang ST; Liu KC; Lay CJ; Chang SM; Tseng CE; Lai CL; Su YC
Emerg Infect Dis; 2008 Nov; 14(11):1818-9. PubMed ID: 18976585
[No Abstract] [Full Text] [Related]
12. Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients.
Koh WJ; Kwon OJ; Lee KS
Korean J Radiol; 2002; 3(3):145-57. PubMed ID: 12271159
[TBL] [Abstract][Full Text] [Related]
13. Persistent B-cell depletion after rituximab for thrombocytopenic purpura.
Bisogno G
Eur J Pediatr; 2007 Jan; 166(1):85-6. PubMed ID: 16896642
[No Abstract] [Full Text] [Related]
14. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view.
Winthrop KL
Future Microbiol; 2010 Mar; 5(3):343-5. PubMed ID: 20210543
[No Abstract] [Full Text] [Related]
16. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
17. [Biological therapy in idiopathic inflammatory myopathies].
Bodoki L; Nagy-Vincze M; Griger Z; Péter A; András C; Dankó K
Orv Hetil; 2014 Jan; 155(1):3-10. PubMed ID: 24379090
[TBL] [Abstract][Full Text] [Related]
18. Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey.
Sailler L; Attane C; Michenot F; Canonge JM; Rostaing L; Arlet-Suau E; Arlet P; Launay F; Montastruc JL; Lapeyre-Mestre M
Br J Clin Pharmacol; 2008 Aug; 66(2):320-2. PubMed ID: 18485050
[No Abstract] [Full Text] [Related]
19. [Nontuberculous mycobacterial infections].
Jimborean G; Nemeş M; Gabor M
Pneumologia; 2001; 50(4):242-9. PubMed ID: 11977501
[No Abstract] [Full Text] [Related]
20. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
